Literature DB >> 15864130

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

Federico Innocenti1, Wanqing Liu, Peixian Chen, Apurva A Desai, Soma Das, Mark J Ratain.   

Abstract

OBJECTIVES: Nine different functional UGT1A enzymes are generated from a single UGT1A gene by alternative splicing, with each enzyme having a unique exon 1. SN-38, the active metabolite of the anticancer agent irinotecan, is metabolized by both UGT1A1 and UGT1A9. We aim to characterize the UGT1A9-UGT1A1 haplotypes in Asians and Caucasians and gain insights on their functional consequences.
METHODS: Asian and Caucasian individuals were genotyped for UGT1A1 and UGT1A9 variants.
RESULTS: A higher frequency of the UGT1A9 -118T10 allele was observed in Asians compared to Caucasians, while the -275T>A and -2152C>T variants were relatively uncommon in Caucasians and not found in Asians. The strongest linkage disequilibrium (LD) was observed between the UGT1A1 -53 and -3156 and between the UGT1A9 -275 and -2152 loci. Lower LD was observed between the -118 UGT1A9 variant and the UGT1A1 variants. Fourteen UGT1A9-UGT1A1 haplotypes were found in Asians, seven of them found to be shared by both populations. Common UGT1A9-UGT1A1 diplotypes were defined, and a difference was observed across the SN-38 glucuronidation rates in Caucasian livers stratified by diplotypes.
CONCLUSION: This study for the first time described common UGT1A9-UGT1A1 haplotypes, highlighting important ethnic differences between Asians and Caucasians. If the functional effect of these haplotypes can be confirmed, this haplotypic information would be applicable to the correct design of prospective clinical studies of irinotecan, as well as of other drugs primarily metabolized by both UGT1A1 and UGT1A9.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864130     DOI: 10.1097/01213011-200505000-00004

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  25 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.

Authors:  Hugo Girard; Lesley M Butler; Lyne Villeneuve; Robert C Millikan; Rashmi Sinha; Robert S Sandler; Chantal Guillemette
Journal:  Mutat Res       Date:  2008-07-16       Impact factor: 2.433

3.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

4.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

5.  Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.

Authors:  Dong Guo; Liang-Fang Pang; Yang Han; Hong Yang; Guo Wang; Zhi-Rong Tan; Wei Zhang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-10-10       Impact factor: 2.953

Review 6.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

Authors:  Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Journal:  Eur J Cancer       Date:  2010-05-23       Impact factor: 9.162

Review 8.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

9.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

10.  Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.

Authors:  Natascia Marino; Joshua W Collins; Changyu Shen; Natasha J Caplen; Anand S Merchant; Yesim Gökmen-Polar; Chirayu P Goswami; Takashi Hoshino; Yongzhen Qian; George W Sledge; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2014-08-03       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.